Hmo

Novel infant-derived probiotic shows promise against malnutrition

22-Apr-2022 By Stephen Daniells

A standard milk-based therapy fortified with a specific strain of gut bacteria may reduce inflammation in the infant gut and promote weight gain in infants with severe acute malnutrition, says a new study.

Study shows HMO levels in breast milk to aid next-gen formula development

12-Apr-2022 By Stephen Daniells

A systematic review of dozens of studies has revealed that levels of the five most prevalent HMOs in breast milk vary widely, and infant formula development should accommodate this variability.

Opportunities & evidence: Human milk oligosaccharides (HMO) health benefits

25-Mar-2022 By Will Chu

In this series of articles, Alwine Kardinaal, Expertise Group Leader at NIZO, talks to NutraIngredients’ Will Chu about prebiotic human milk oligosaccharides (HMOs) health benefits and applications.

HMO supplements may improve gut health for adults with IBS: DSM study

29-Oct-2021 By Stephen Daniells

People with irritable bowel syndrome (IBS) may benefit from supplements of human milk oligosaccharides (HMOs), with a new study showing modulation of the gut microbiota, fecal and plasma metabolite profiles.

Chr. Hansen publishes first scientific study of HMO mix in natural concentrations in infant formula

30-Aug-2021 By Jim Cornall

Human milk oligosaccharides (HMOs) are the third most abundant components exclusively found in human breast milk.

Inbiose applies for FDA GRAS approval of four new fermentation-produced HMOs

06-Jul-2021 By Jim Cornall

Belgian biotech company Inbiose, which develops human milk oligosaccharides (HMOs), has submitted its application for a Generally Recognized as Safe (GRAS) approval by the US Food & Drug Administration (FDA) of four HMOs.

Chr. Hansen and Nestlé settle HMO patent litigation

17-May-2021 By Will Chu

Chr. Hansen and Nestlé have settled a legal dispute involving alleged infringements on Human Milk Oligosaccharide (HMO) patents arising from October 2020’s acquisition of Jennewein Biotechnologie.

HMO supplementation may boost bowel function and help adults with IBS: Study

12-May-2021 By Stephen Daniells

Supplementation with the human milk oligosaccharides (HMOs) HMOs 2'-fucosyllactose (2'FL), and lacto-N-neotetraose (LNnT) may normalize bowel function and improve bloating and IBS severity in adults, says a new study.

Culturelle unveils medical food for IBS support

19-Apr-2021 By Danielle Masterson

Culturelle Probiotics has just entered the medical food market by introducing Culturelle IBS Complete Support.

HMO levels in human milk linked to infant cognitive development: Abbott Study

25-Feb-2021 By Stephen Daniells

Levels of two specific human milk oligosaccharides (HMOs) are linked with measure of infant cognitive development, says a pilot study led by R&D Abbott Nutrition.

Improved strain-specific use of HMOs identified in DuPont-backed study

20-Oct-2020 By Will Chu

Probiotic strain specificity is crucial if the benefits of human milk oligosaccharides (HMOs) such as 2′-fucosyllactose are to be passed on to the infant, according to a DuPont-sponsored study.

Gut simulation expands health benefits of HMOs in adults

28-Sep-2020 By Stephen Daniells

The potential health effects of human milk oligosaccharides (HMOs) for adults may extend beyond just promoting the growth of beneficial Bifidobacteria to also impacting immune function and the gut barrier, says a new study.

Chr. Hansen adds Jennewein HMO expertise to microbial platform in €310m deal

24-Sep-2020 By Will Chu

Chr. Hansen is to acquire Jennewein Biotechnologie for €310m in a deal designed to merge the bioscience firm’s probiotic interests with the gains Jennewein have made in the Human Milk Oligosaccharides (HMO) market.

Probiotics help preterm babies establish a 'normal' microbiome: Study

27-Aug-2020 By Danielle Masterson

Specific strains of probiotic Bifidobacterium and Lactobacillus bacteria given to preterm babies in combination with breast milk may help to build microbial populations and gut health that mirror those of full-term babies, suggests data from the Baby-Associated...

HMOs for NEC: Abbott-Johns Hopkins researchers unlock breastmilk prebiotics intestinal mechanism

09-Apr-2020 By Stephen Daniells

Human milk oligosaccharides (HMOs) may prevent the development of necrotizing enterocolitis (NEC) in premature infants by inhibiting a specific receptor in the intestine linked to inflammation, researchers from Johns Hopkins and Abbott report for the...

3-FL demonstrates safe use for food and dietary supplements: Study

25-Feb-2020 By Danielle Masterson

DuPont Nutrition & Biosciences continues its foray into digestive health by ramping up research on human milk oligosaccharides (HMOs).

DSM acquires HMO firm Glycom in €765m deal

25-Feb-2020 By Will Chu

Royal DSM has reached agreement to acquire Danish Human Milk Oligosaccharide (HMO) supplier Glycom in a deal worth €765m.

NIU’s Global Round-Up: More infant milk formulators are focusing their efforts on gut and brain health, breast milk linked to baby growth, and more

24-Feb-2020 By Danielle Masterson

What’s happened across the Nutra-verse over the past seven days? Stay on top of things with our weekly round-up of key news from across the globe.

BASF joins the HMO club with 2’-FL launch

23-Oct-2019 By Stephen Daniells

Human milk oligosaccharides (HMOs) are the “hot new thing” said an expert recently, as BASF announced the US launch of its 2’-FL (2’-fucosyllactose) ingredient, which is branded Prebilac.

Vitafoods Asia 2018

HMOs a goldmine of human health applications beyond infant formula: DuPont expert

12-Sep-2018 By Cheryl Tay

Human milk oligosaccharides (HMOs) have extensive potential to offer a range of health benefits in products beyond infant formula, DuPont's global business director for HMOs, Steen Lyck, said at Vitafoods Asia on Tuesday.